Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.58 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.58 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13761627 | 0.99 | KDM4E (0.67) | KDM4EALDH1A1SMN1; SMN2LTA4HMEN1 | |
| SCHEMBL12780023 | 0.90 | KMT2A (0.64) | KDM4EALDH1A1SMN1; SMN2LTA4HMEN1 | |
| SCHEMBL13761603 | 0.87 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2LTA4HMEN1 | |
| SCHEMBL11937211 | 0.87 | ALDH1A1 (0.59) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14970473 | 0.84 | LTA4H (0.81) | KDM4EALDH1A1SMN1; SMN2LTA4HKMT2A | |
| SCHEMBL11244902 | 0.84 | LTA4H (0.81) | KDM4EALDH1A1SMN1; SMN2LTA4HKMT2A | |
| SCHEMBL11947324 | 0.83 | KDM4E (0.74) | KDM4ELTA4HMEN1KMT2APSMB1 | |
| Hydrochloric Acid SCHEMBL14969107 | 0.83 | LTA4H (0.79) | KDM4EALDH1A1SMN1; SMN2LTA4HKMT2A | |
| SCHEMBL270794 | 0.81 | KDM4E (1.00) | KDM4ELTA4HMEN1KMT2APSMB1 | |
| SCHEMBL13165290 | 0.81 | ALDH1A1 (0.64) | KDM4EALDH1A1SMN1; SMN2HRH3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380588-A1 | Novel Compounds and Uses Thereof | OXFORD FINANCE LLC | 2021-12-09 | — | — | US | disclosed |
| US-10954244-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | KALA BIO, Inc. | 2020-05-21 | — | — | US | disclosed |
| US-10544151-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10351570-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190023710-A1 | NOVEL COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2019-01-24 | — | — | US | disclosed |
| US-9988386-B2 | Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof | Kata Pharmaceuticals, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988386-B2 | Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof | Kata Pharmaceuticals, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-13 | — | — | US | disclosed |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-11-13 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | KDM4E 1356/4885ALDH1A1 3662/4885SMN1; SMN2 3530/4885 |
| US-20100256367-A1 | Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives | ARSA, BMP2, BMP1 | KDM4E 1873/4885ALDH1A1 721/4885SMN1; SMN2 1743/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | KDM4E 1689/4885ALDH1A1 3235/4885SMN1; SMN2 4746/4885 |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | KDM4E 3246/4885ALDH1A1 1517/4885SMN1; SMN2 4782/4885 |
| US-20190023710-A1 | NOVEL COMPOUNDS AND USES THEREOF | RB1, VEGFA, UACA | KDM4E 3496/4885ALDH1A1 1460/4885SMN1; SMN2 4828/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | KDM4E 1689/4885ALDH1A1 3235/4885SMN1; SMN2 4746/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | KDM4E 1689/4885ALDH1A1 3235/4885SMN1; SMN2 4746/4885 |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | KDM4E 3246/4885ALDH1A1 1517/4885SMN1; SMN2 4782/4885 |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | KDM4E 3246/4885ALDH1A1 1517/4885SMN1; SMN2 4782/4885 |
| US-10544151-B2 | Compounds and uses thereof | RB1, VEGFA, KDR | KDM4E 3193/4885ALDH1A1 1409/4885SMN1; SMN2 4782/4885 |
| US-10954244-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | KDM4E 3200/4885ALDH1A1 1477/4885SMN1; SMN2 4744/4885 |
| US-20080280901-A1 | Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives | CYP24A1, SOST, ACP3 | KDM4E 2169/4885ALDH1A1 537/4885SMN1; SMN2 2523/4885 |
| US-10351570-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | KDM4E 3200/4885ALDH1A1 1477/4885SMN1; SMN2 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.